RANI (Rani Therapeutics Holdings) ROE % Adjusted to Book Value : -44.30% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Rani Therapeutics Holdings ROE % Adjusted to Book Value?

Rani Therapeutics Holdings's ROE % for the quarter that ended in Sep. 2024 was -911.23%. Rani Therapeutics Holdings's PB Ratio for the quarter that ended in Sep. 2024 was 20.57. Rani Therapeutics Holdings's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -44.30%.

Rani Therapeutics Holdings ROE % Adjusted to Book Value Historical Data

The historical data trend for Rani Therapeutics Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rani Therapeutics Holdings ROE % Adjusted to Book Value Chart

Rani Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

-17.93

-20.33

Rani Therapeutics Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-55.04	-27.78	-26.69	-14.98	-44.30

Competitive Comparison of Rani Therapeutics Holdings's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Rani Therapeutics Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rani Therapeutics Holdings's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Rani Therapeutics Holdings's ROE % Adjusted to Book Value falls into.

Rani Therapeutics Holdings ROE % Adjusted to Book Value Calculation

Rani Therapeutics Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-136.64%	/	6.72
	=	-20.33%

Rani Therapeutics Holdings's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-911.23%	/	20.57
	=	-44.30%

Rani Therapeutics Holdings ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Rani Therapeutics Holdings's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Rani Therapeutics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rani Therapeutics Holdings Inc (NAS:RANI) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

2051 Ringwood Avenue, San Jose, CA, USA, 95131

Website

https://www.ranitherapeutics.com

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.

Executives

South Cone Investments Limited Partnership	10 percent owner	AVENIDA PRESIDENTE RIESCO 5711 OFICINA 1, LAS CONDES, SANTIAGO F3 7550000
Talat Imran	director, officer: CEO	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
Quiroga Cortes Isidoro Alfonso	10 percent owner	9020 N CAPITAL OF TEXAS HWY, SUITE I-260, AUSTIN TX 78759
Jean Luc Butel	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Maulik Nanavaty	director	BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Kate Mckinley	officer: CHIEF BUSINESS OFFICER	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Svai S Sanford	officer: CFO	C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE., SAN JOSE CA 95131
Eric Groen	officer: General Counsel	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Mir Hashim	officer: Chief Scientific Officer	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Lake One Llc	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Aequanimitas Limited Partnership	10 percent owner	LEONEL AGUIRRE 1830, UNIT 101, MONTEVIDEO X3 11500
Mir A Imran	director
Andrew Farquharson	director	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
Laureen Debuono	director
Lisa Ann Rometty	director	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131